
Sign up to save your podcasts
Or


Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:
By JAMA Network4.6
162162 ratings
Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:

38,430 Listeners

43,687 Listeners

27,011 Listeners

134 Listeners

321 Listeners

549 Listeners

701 Listeners

504 Listeners

6,467 Listeners

298 Listeners

264 Listeners

3,374 Listeners

21 Listeners

16 Listeners

8 Listeners

7 Listeners

19 Listeners

31 Listeners

94 Listeners

518 Listeners

367 Listeners

18 Listeners

375 Listeners